Fiori G P
Arch Sci Med (Torino). 1976 Apr-Jun;133(2):127-34.
The tolerance of a new pivampicillin and dicloxacillin association, especially at high doses and during prolonged treatment, was assessed by administering two 600 mg tablets (350 mg pivampicillin + 250 mg dicloxacillin) every 6 or 8 hr (according to the seriousness of the diseases) to 53 patients with acute infection of varying site and aetiology. Microbiological, radiological and blood chemistry data were collected with reference to the disease involved, along with clinical and laboratory data capable of demonstrating the eventual appearance of unwanted side-effects referable to the association. The results showed that the association was therapeutically effective and well tolerated at high doses given over long periods.
通过每6或8小时（根据疾病的严重程度）给53例患有不同部位和病因的急性感染患者服用两片600毫克片剂（350毫克匹氨西林+250毫克双氯西林），评估了一种新的匹氨西林和双氯西林联合用药的耐受性，尤其是在高剂量和长期治疗期间。参照所涉及的疾病收集了微生物学、放射学和血液化学数据，以及能够证明该联合用药最终出现不良反应的临床和实验室数据。结果表明，该联合用药在长期高剂量给药时具有治疗效果且耐受性良好。
